My Health News » Medical News Today - Cholesterol

Feeds

164867 items (164867 unread) in 46 feeds

World Health Organization (462 unread)

• WHO news (251 unread)
• Disease Outbreak News (211 unread)

Media (128004 unread)

• Reuters Health eLine (5187 unread)
• CNN Health (1931 unread)
• NPR Health and Science (2586 unread)
• ABC News: Health (3885 unread)
• CBSnews.com: Health News (4511 unread)
• BBC Health News (3762 unread)
• CBC Health and Science News (3016 unread)
• Australia ABC News: Health (7721 unread)
• China Xinghua Health News (3974 unread)
• New York Times: Health (8872 unread)
• USATODAY.com Health - Top Stories (2939 unread)
• The Seattle Times: Health (2304 unread)
• International Herald Tribune: Health and Science (1983 unread)
• HeraldToday.com: Health (1832 unread)
• WebMD Health Headlines (4443 unread)
• MedicineNet Daily News (7011 unread)
• Medical News Today (39030 unread)
• iVillage Health (956 unread)
• Topix.net - Health (3398 unread)
• Newsvine - health (18663 unread)

Bird Flu (3515 unread)

• MSNBC.com: Bird Flu (143 unread)
• Topix.net - Bird Flu (2287 unread)
• Medical News Today - Bird Flu/Avian Flu (580 unread)
• MedicineNet Cold and Flu General (505 unread)

Diabetes (5648 unread)

• Topix.net - Diabetes (3040 unread)
• Medical News Today - Diabetes (1930 unread)
• MedicineNet Diabetes General (678 unread)

Cholesterol (2462 unread)

• Topix.net - Cholesterol (1117 unread)
• Medical News Today - Cholesterol (396 unread)
• MedicineNet Cholesterol General (949 unread)

Cancer (11808 unread)

• MSNBC.com: Cancer (527 unread)
• Topix.net - Cancer (2963 unread)
• Medical News Today - Breast Cancer News (1539 unread)
• Medical News Today - Cancer/Oncology News (5215 unread)
• MedicineNet Cancer General (1564 unread)

HIV (7247 unread)

• Topix.net - HIV/AIDS (2662 unread)
• Medical News Today - HIV/AIDS News (4342 unread)
• MedicineNet HIV General (243 unread)

Women (4402 unread)

• MSNBC.com: Women's Health (328 unread)
• Medical News Today - OBGYN News (2812 unread)
• MedicineNet Womens Health General (1262 unread)

Men (1319 unread)

• MSNBC.com: Men's Health (136 unread)
• Medical News Today - Men's health News (529 unread)
• MedicineNet Mens Health General (654 unread)

Medical News Today - Cholesterol (30 unread)

• eHealthMe.com Offers New Look At Statin Side Effects Study, More Research May Be Needed

  Posted: September 7th, 2008, 3:00am EDT

  In 2004, the FDA sponsored a study on occurrences of rhabdomyolysis, a sometimes deadly side effect of cholesterol-lowering statins, generally believed to be rare after the withdrawal of cerivastatin. The FDA study looked at patients using statins for a period of one year, with results showing that only 0.44 in 10,000 patients will develop this sometimes life-threatening condition. The creators of eHealthMe.

• Elderly Benefit From Cholesterol Drugs To Lower Risk Of Stroke

  Posted: September 6th, 2008, 6:00am EDT

  Elderly people who take a cholesterol drug after a stroke or mini-stroke lower their risk of having another stroke just as much as younger people in the same situation, according to research published in the September 3, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

• New Research Supports Need For Healthy Diet In Conjunction With Statins To Effectively Lower Cholesterol

  Posted: September 5th, 2008, 4:00am EDT

  New research commissioned by Flora pro.activ revealed that two thirds of GPs polled feel that it is very important for patients on cholesterol-lowering medication to also ensure they eat a healthy diet to improve heart health. According to recent NICE guidance on the management of Familial Hypercholesterolaemia (FH), first-line treatment for FH should be statins.

• Cholesterol In The News: Answers And More Questions

  Posted: September 4th, 2008, 4:00am EDT

  Understanding cholesterol is more than figuring out what's good and bad. Although much is known about this waxy substance that's in all body cells and its relationship with heart disease, much is still uncertain. Doctors suspect that the relationship may be more complicated than previously believed. The September issue of Mayo Clinic Women's HealthSource provides an overview of cholesterol and recent news about cholesterol medications.

• Ezetimibe And Cancer Link Still Not Clear Say Experts

  Posted: September 3rd, 2008, 5:00am EDT

  The link between cholesterol-lowering drug ezetimibe (marketed as Vytorin) and cancer is still not clear, wrote the editors of the leading medical journal New England Journal of Medicine (NEJM). More time is needed to assess the drug, they said, and in the meantime patients and doctors will have to live with the uncertainty.

• Survey Among European Cardiologists Points To A Gap In Cardiovascular Disease Management

  Posted: September 3rd, 2008, 4:00am EDT

  Cardiologists in Europe agree that reducing LDLcholesterol (LDL-C or "bad" cholesterol) is the most important consideration when treating dyslipidaemia (abnormal blood lipids). A majority of cardiologists also agree that in addition to lowering LDL-C, raising HDL-cholesterol (HDL-C or "good" cholesterol) and reducing triglycerides are important factors in choosing dyslipidaemia treatment.

• Patients Who Discontinue Statin Therapy May Be More Likely To Die, New Observational Study Shows

  Posted: September 2nd, 2008, 4:00am EDT

  The results of a new observational study presented recently at the showed that patients who stop taking their prescribed statins have a four-fold increased risk of death during the first year following an acute coronary syndrome. The study included 2,234 patients who were prescribed statin therapy after an acute coronary syndrome. Patients were followed for one year after discharge from the hospital.

• Issues On Cholesterol: Diet, Statins And Genetics

  Posted: September 1st, 2008, 8:00am EDT

  Genetic lipoprotein disorders are frequently seen in patients with premature coronary artery disease (CAD). An example of strong genetic predisposition is the disorder: familial hypercholesterolemia, where a single gene defect (the low density lipoprotein receptor) contributes to most of the familial expression of CAD.

• NICE Recognises Role Of High Intensity Statin Therapy In Patients With Familial Hypercholesterolaemia, UK

  Posted: August 29th, 2008, 5:00am EDT

  AstraZeneca welcomes the recommendations by the National Institute for Health and Clinical Excellence (NICE) on the treatment of Familial Hypercholesterolaemia (FH) 1, a genetic condition resulting in high cholesterol levels. As part of its comprehensive review on the identification and management of people with FH, NICE has recommended that adults with the condition be treated with high intensity statins in order to reduce LDL-cholesterol (LDL-C) levels by 50%.

• Tepnel Announces New DNA Test For Early Detection Of Familial Hypercholesterolaemia

  Posted: August 29th, 2008, 4:00am EDT

  Just ahead of the expected release of clinical practice guidelines on Familial Hypercholesterolaemia (FH) by the influential National Institute for Clinical Excellence (NICE), Tepnel Life Sciences PLC (AIM: TED) today announced the launch of a DNA test for the early detection of FH, a genetic condition that predisposes individuals to high blood cholesterol levels and increased risk of cardiovascular disease.

• New NICE Guidelines Are Set To Reduce Premature Deaths In People Who Have Inherited High Cholesterol

  Posted: August 28th, 2008, 5:00am EDT

  The National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Primary Care have today (27 August 2008) published a guideline on the care and treatment of adults and children/young people with familial hypercholesterolaemia (FH), a type of high cholesterol that is caused by an inherited genetic mutation.

• High Cholesterol Levels Drop Naturally In Children On High-Fat Anti-Seizure Diet, Hopkins Study Show

  Posted: August 28th, 2008, 4:00am EDT

  Elevated cholesterol levels return to normal or near normal levels over time in four out of 10 children with uncontrollable epilepsy treated with the high-fat ketogenic diet, according to results of a Johns Hopkins Children's Center study reported in the Journal of Child Neurology. The study appears online ahead of print here.

• Olive Leaf Extract Can Help Tackle High Blood Pressure And Cholesterol

  Posted: August 27th, 2008, 6:00am EDT

  Taking 1000mg of a specific olive leaf extract (EFLA®943) can lower cholesterol and lower blood pressure in patients with mild hypertension (high blood pressure). These findings came from a 'Twins' trial, in which different treatments were given to identical twins. By doing this, researchers could increase the power of their data by eliminating some of the uncertainties caused by genetic variations between individual people.

• Low Cholesterol Associated With Cancer In Diabetics

  Posted: August 26th, 2008, 3:00am EDT

  Low levels of LDL cholesterol as well as high levels are associated with cancer in patients with type 2 diabetes, found a prospective cohort study published in CMAJ.

• New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9, A Genetically Validated Regulator Of LDL Metabolism

  Posted: August 14th, 2008, 4:00am EDT

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that new pre-clinical data from its hypercholesterolemia program was published in Proceedings of the National Academy of Sciences (Frank-Kamenetsky, M., et al (August 11, 2008) Proc. Natl Acad. Sci. USA, 10.1073/pnas.0805434105).

• Cholesterol Drug Plays Role In Melanoma Remission

  Posted: August 13th, 2008, 5:00am EDT

  A drug widely used to treat high cholesterol is helping beat cancer. Lovastatin is part of a new cancer treatment that has arrested or eradicated tumors in more than 80% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today. Lovastatin, the first of the statin group of lipid fighters, was introduced in 1980.

• Designer RNA Fights High Cholesterol, Researchers Find

  Posted: August 12th, 2008, 7:00am EDT

  Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.

• Detailed Results From The SEAS Study To Be Presented At European Society Of Cardiology Congress 2008

  Posted: August 11th, 2008, 4:00am EDT

  Topline results from the SEAS trial, which were first disclosed publicly at a press conference in London on 21st July, have since then caused heated reaction. The results showed that reducing levels of LDL-cholesterol with a proprietary combination of simvastatin and ezetimibe in patients with aortic stenosis had no more effect on major cardiovascular events (the study's primary endpoint) than with placebo.

• Greater Specificity Of Cardiac Risk Tests With The Randox HDL And LDL Clearance Method

  Posted: August 11th, 2008, 4:00am EDT

  With the revolutionary Randox HDL and LDL clearance method, part of the lipid profile, specificity of testing and accuracy of diagnosis is vastly improved. This has replaced traditional assessment of cardiovascular disease (CVD) risk which frequently provided inaccurate and insufficient information for the clinician, possibly leading to misdiagnosis of the patient.

• Genzyme And Isis Begin Second Phase 3 Trial Of Mipomersen

  Posted: August 7th, 2008, 4:00am EDT

  Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol. It is the first of four new trials the companies plan to initiate by the end of this year, and the second late-stage study of mipomersen, a novel lipid-lowering drug that utilizes antisense technology.

• Lowering Cholesterol Early In Life Could Save Lives - Intervention Should Begin In Childhood, Say UC San Diego Scientists

  Posted: August 5th, 2008, 5:00am EDT

  With heart disease maintaining top billing as the leading cause of death in the United States, a team of University of California, San Diego School of Medicine physician-researchers is proposing that aggressive intervention to lower cholesterol levels as early as childhood is the best approach available today to reducing the incidence of coronary heart disease.

• Karo Bio Announces Successful Phase II Study With Eprotirome In Combination With Statin

  Posted: August 5th, 2008, 4:00am EDT

  Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein (a) and was safe and well tolerated.

• New Data On Average National Cholesterol Levels Provides Benchmark To Measure Progress To Treatment Targets, UK

  Posted: July 29th, 2008, 3:00am EDT

  New research from over 223,000 patients published in the Primary Care Cardiovascular Journal (PCCJ)1, suggests that total cholesterol (TC) levels in statin-treated UK patients are higher than that of the general population. The recent Health Survey for England (HSE 2006) 2 found that the mean TC was 5.3 mmol/L in men and 5.4 mmol/L in women. This is in contrast to the average TC of 6.

• 'Tredaptive'® (Nicotinic Acid/Laropiprant) Authorised In The European Union: New Lipid-Modifying Therapy To Treat LDL-C, HDL-C And Triglycerides

  Posted: July 23rd, 2008, 3:00am EDT

  Merck Sharp & Dohme Limited (MSD) announced recently that 'Tredaptive' (nicotinic acid/laropiprant) 1000 mg/20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidaemia and primary hypercholesterolaemia, has been authorised for marketing in the 27 member countries of the European Union (EU) and Iceland and Norway.1 'Tredaptive' combines nicotinic acid (niacin) and laropiprant, a novel flushing pathway inhibitor.

• Results From The SEAS (Simvastatin And Ezetimibe In Aortic Stenosis) Study

  Posted: July 22nd, 2008, 6:00am EDT

  The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis. Aortic stenosis (which involves partial blockage of the aortic valve in the heart) is a relatively common disease among older people in Western populations. Left untreated, it can progress to death from heart failure or cardiac arrest.

• Independent Analyses Of The SEAS, SHARP And IMPROVE-IT Studies Of Statin Ezetimibe

  Posted: July 22nd, 2008, 6:00am EDT

  The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) proposed that the hypothesis-generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE-IT trials of ezetimibe, and reporting on the overall findings to the relevant regulatory authorities, independently of the drug manufacturers.

• VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels And Atherosclerosis

  Posted: July 22nd, 2008, 5:00am EDT

  Using the VAP Cholesterol Test from Atherotech, researchers have identified a link between adiponectin and heart disease progression. The information could help physicians trying to pinpoint the most effective cholesterol and heart disease risk-lowering treatments in at-risk patients.

• Low Carb And Mediterranean May Be Effective Alternatives To Low Fat Diets, Study

  Posted: July 17th, 2008, 5:00am EDT

  A new large scale 2 year study by an international team of scientists concluded that Mediterranean and low carbohydrate diets may be just as safe and effective as standard medically prescribed low fat diets for losing weight and if continued beyond the weight loss target, may confer long term health benefits. A particularly noteworthy feature of the study is the high proportion of participants who stuck to the diets for the whole 2 years: 85 per cent.

• Low Carb And Mediterranean May Be Effective Alternatives To Low Fat Diets, Study

  Posted: July 17th, 2008, 5:00am EDT

  A new large scale 2 year study by an international team of scientists concluded that Mediterranean and low carbohydrate diets may be just as safe and effective as standard medically prescribed low fat diets for losing weight and if continued beyond the weight loss target, may confer long term health benefits. A particularly noteworthy feature of the study is the high proportion of participants who stuck to the diets for the whole 2 years: 85 per cent.

• For Children With Neurofibromatosis Type 1, Statin Does Not Improve Cognitive Function

  Posted: July 16th, 2008, 3:00am EDT

  For children with neurofibromatosis type 1 (NF1), a genetic disorder that often leads to learning disability, cognitive function is not improved by the statin simvastatin, according to an article released on July 15 in JAMA. NF1 is characterized by the development of tumors in Schwann cells in the nervous system.